Navigation Links
Oncothyreon initiates Phase 1b trial of PX-12 in patients with advanced metastatic cancer
Date:6/11/2008

infusion daily for five days of a 21-day cycle in patients with advanced pancreatic cancer who have progressed on gemcitabine or a gemcitabine-containing regimen.

About Oncothyreon

Oncothyreon is a biotechnology company specializing in the development of innovative therapeutic products for the treatment of cancer. Oncothyreon's goal is to develop and commercialize novel synthetic vaccines and targeted small molecules that have the potential to improve the lives and outcomes of cancer patients. For more information, visit http://www.oncothyreon.com.

Forward-Looking Statements

In order to provide Oncothyreon's investors with an understanding of its current intentions and future prospects, this release contains statements that are forward looking, including statements related to the therapeutic and commercial potential of PX-12; future clinical development plans; the details of clinical trials; and the anticipated future size of the market for PX-12. These forward-looking statements represent Oncothyreon's intentions, plans, expectations and beliefs and are based on its management's experience and assessment of historical and future trends and the application of key assumptions relating to future events and circumstances.

Forward-looking statements involve risks and uncertainties, including risks and uncertainties related to Oncothyreon's business and the general economic environment. Many of these risks and uncertainties are beyond Oncothyreon's control. These risks, uncertainties and other factors could cause our actual results to differ materially from those projected in forward-looking statements. Risks, uncertainties, and assumptions include those predicting the timing, duration and results of clinical trials, the timing and results of regulatory reviews, and the safety and efficacy of PX-12. There can be no guarantee that the results of earlier trials will be predictive of
'/>"/>

SOURCE Oncothyreon Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Oncothyreon to receive milestone payment
2. Oncothyreon Reports First Quarter 2008 Financial Results
3. Oncothyreon files investigational new drug application for PX-866 oncology compound
4. Data for Oncothyreons PX-12 and PX-866 presented at AACR Annual Meeting
5. Oncothyreon announces data from multiple small molecule programs to be presented at American Association of Cancer Research Annual Meeting
6. Oncothyreon announces effectiveness of shelf registration statement
7. Oncothyreon announces issuance of patent for PX-867
8. Oncothyreon to present at upcoming investment conferences
9. Oncothyreon reports full year and fourth quarter 2007 financial results
10. Oncothyreon announces March 10th webcast of fourth quarter and full year financial results conference call
11. Oncothyreons PX-478 is effective in preclinical model of human lung cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... Philadelphia, PA (PRWEB) July 29, 2014 Philadelphia’s ... to help businesses get their start. The Innovation Center ... and the University City Science Center to help ... its doors on Monday, July 28. , ... corner of 34th and Market Streets, is the new home ...
(Date:7/29/2014)... Seattle, WA (PRWEB) July 29, 2014 ... central IRB services, has been awarded accreditation by ... (IASSC) for its Lean Six Sigma Deployment ... eliminate waste and improve performance. , Quorum’s Lean ... granted the Accredited Deployment Program designation. The designation ...
(Date:7/29/2014)... 2014 Eppendorf Centrifuge 5427 R ... Eppendorf 5427 R is geared towards high-end applications like ... is targeted towards work requiring high sample throughput. Pipette.com ... it compliments their extensive 16, 48, and 64 multichannel ... tubes, PCR tubes, PCR strip tubes, and more. ...
(Date:7/29/2014)... (PRWEB) July 29, 2014 EXpressLO LLC, ... lift out specimen preparation solutions, has been granted patent ... for specimen manipulation methods incorporating a unique specimen carrier ... This is the second company patent for EXpressLO LLC ... , These complementary patents extend EXpressLO’s portfolio ...
Breaking Biology Technology:Innovation Center @3401 Opens for Business; DreamIt Ventures and Point.io First Residents 2Innovation Center @3401 Opens for Business; DreamIt Ventures and Point.io First Residents 3Quorum Review IRB Accredited by IASSC for Lean Six Sigma Deployment Program 2Quorum Review IRB Accredited by IASSC for Lean Six Sigma Deployment Program 3International Pipette Distributor, Pipette.com Announces the Addition of the Eppendorf Centrifuge 5427 R to Their Product Portfolio 2EXpressLO LLC Granted Second U.S. Patent for Innovative Specimen Preparation Methods 2
... Company confirms commercial expression levels of ... status of native Apo AI -, CALGARY, ... biotechnology company developing a portfolio of therapeutic,proteins for ... on July 12, 2007 announcing that the Company ...
... Switzerland, Aug. 21 Roche (SWX: ROG.VX; RO.S),a world-leading ... has extended its offer to acquire all of the,outstanding ... VMSI ),to 5:00 p.m., New York City time on ... to expire at 5:00 p.m., New York City,time, on ...
... Republic, Aug. 21 Medpace,Inc., a leading ... has completed the acquisition of Monax s.r.o., ... Prague, Czech,Republic. This move strengthens the Medpace ... to provide full service clinical research management,within ...
Cached Biology Technology:SemBioSys updates Apo AI development program 2SemBioSys updates Apo AI development program 3SemBioSys updates Apo AI development program 4Roche Extends Tender Offer for Ventana 2Roche Extends Tender Offer for Ventana 3Roche Extends Tender Offer for Ventana 4Medpace Strengthens Presence in Central Europe 2
(Date:7/29/2014)... latest research from the University of Adelaide ... of many preterm children can perform almost as well as ... University,s Robinson Research Institute has found that as ... early life, their cognitive abilities as a teenager can potentially ... results of the study, published in this month,s issue of ...
(Date:7/29/2014)... types of cell, including sperm, bacteria and algae, ... These protrusions, about one-hundredth of a millimetre long, ... fluid. Similar, shorter structures called cilia are found ... perform roles such as moving liquids over the ... versatile: they transport mucus and expel pathogens from ...
(Date:7/28/2014)... additional coral communities showing signs of damage from the Deepwater ... spill in the Gulf of Mexico. The discovery was made ... at Penn State University. A paper describing this work and ... of Mexico will be published during the last week of ... Proceedings of the National Academy of Sciences . , ...
Breaking Biology News(10 mins):Preterm children's brains can catch up years later 2Microscopic rowing -- without a cox 2Microscopic rowing -- without a cox 3Impact of Deepwater Horizon oil spill on coral is deeper and broader than predicted 2
... neurons communicate. Neurotransmitter molecules released from the presynaptic terminal ... the other, binding to receptors that lead to propagation ... by experts in the field, The Synapse ... complex structures of the pre- and postsynaptic regions, as ...
... eyes sensitive to ultraviolet light, which they may use to ... new Nova Southeastern University study suggests. Tamara Frank, Ph.D., ... Oceanographic Center, who is the principal investigator of the study, ... dark area at the ocean bottom ---- may be using ...
... players on your favourite football team were smaller than their ... defenseless, they would become easy prey for other teams. Similarly, ... organisms vulnerable to their predators, which may pose a serious ... calcium levels the organisms grow slower and cannot build their ...
Cached Biology News:Deep-sea crabs seek food using ultraviolet vision 2Deep-sea crabs seek food using ultraviolet vision 3Changes in water chemistry leave lake critters defenseless 2